Skip to main content

Advertisement

Table 4 Association between eNOS Haplotypes and PFS and OS

From: eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial

eNOS haplotypes CT + B CT
n Median PFS (95% CI) HR (95% CI) P* n Median PFS (95% CI) HR (95% CI) P*
Haplo1/Haplo1 24 17.8 (8.1–22.3) 0.46 (0.27–0.78)   33 10.3 (8.0–15.0) 0.71 (0.46–1.10)  
Other 90 9.6 (8.3–10.9) 1.00 0.004 86 9.0 (7.8–9.6) 1.00 0.123
Haplo2/Haplo2 15 13.1 (7.2–15.7) 0.82 (0.46–1.46)   16 9.9 (5.9–11.5) 1.44 (0.82–2.51)  
Other 99 9.6 (8.3–11.3) 1.00 0.501 107 9.0 (8.3–10.2) 1.00 0.199
Haplo1/Haplo1 + Haplo2/Haplo2 39 15.0 (10.6–18.7) 0.48 (0.30–0.75)   49 10.3 (8.3–11.5) 0.88 (0.60–1.31)  
Other 75 9.1 (7.4–10.1) 1.00 0.001 70 9.0 (7.2–9.6) 1.00 0.542
  1. *Adjusted for CT (FOLFOX4/FOLFIRI), gender, age, KRAS status, tumor localization (rectum/colon).
eNOS haplotypes CT + B CT
n Median OS (95% CI) HR (95% CI) P* n Median OS (95% CI) HR (95% CI) P*
Haplo1/Haplo1 24 31.6 (19.3–nr) 0.46 (0.24–0.86)   33 23.2 (16.8–39.7) 0.80 (0.49–1.31)  
Other 90 21.3 (15.9–25.2) 1.00 0.016 86 20.8 (18.2–24.5) 1.00 0.379
Haplo2/Haplo2 15 34.5 (13.1–42.9) 0.70 (0.37–1.31)   16 21.3 (14.4–26.4) 1.35 (0.73–2.50)  
Other 99 21.3 (16.4–24.7) 1.00 0.260 107 21.6 (19.2–27.1) 1.00 0.331
Haplo1/Haplo1 + Haplo2/Haplo2 39 34.5 (23.4–38.4) 0.42 (0.25–0.72)   49 21.7 (18.8–29.6) 0.95 (0.61–1.48)  
Other 75 20.5 (14.4–22.7) 1.00 0.002 70 20.8 (18.2–27.1) 1.00 0.829
  1. *Adjusted for CT (FOLFOX4/FOLFIRI), gender, age, KRAS status, tumor localization (rectum/colon).